

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

GalliaPharm 1.11 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
 Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 1.48 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 1.85 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
 Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 2.22 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
 Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 2.59 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 2.96 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 3.33 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
 Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer


Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.



The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.

Package leaflet: Information for the patient

GalliaPharm 3.70 GBq radionuclide generator

Gallium (^{68}Ga) chloride solution

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GalliaPharm is and what it is used for
2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
3. How gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used
4. Possible side effects
5. How GalliaPharm is stored
6. Contents of the pack and other information

1. What GalliaPharm is and what it is used for

GalliaPharm is a germanium (^{68}Ge)/gallium (^{68}Ga) radionuclide generator, a device used to obtain a solution of gallium (^{68}Ga) chloride. Gallium (^{68}Ga) chloride is a radioactive substance that is handled by specialised doctors (nuclear medicine doctors) and pharmacists trained to work with radioactive materials. Gallium (^{68}Ga) chloride is not intended for direct use in patients, but is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound, here ^{68}Ga .

Only medicines that have been specifically developed and approved for radiolabelling with ^{68}Ga undergo the radiolabelling procedure with gallium (^{68}Ga) chloride. These radiolabelled medicines can recognise and attach to particular types of cells in the body and take the radioactive ^{68}Ga to these cells in your body. The low amount of radioactivity present in the ^{68}Ga -labelled medicine can be detected from outside of the body by special cameras. This may help your doctor with the diagnosis. Please refer to the Package Leaflet of the medicine that is to be radiolabelled with gallium (^{68}Ga) chloride for more information.

The nuclear medicine doctor will explain to you in more detail what type of examination will be performed.

The use of a ^{68}Ga -labelled medicine does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the ^{68}Ga -labelled medicine overcomes the risk due to radiation.

2. What you need to know before the gallium (^{68}Ga) chloride solution obtained with GalliaPharm is used

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must not be used

- if you are allergic to gallium (^{68}Ga) chloride or any of the other ingredients of this medicine (listed in section 6).

If you are using a ^{68}Ga -labelled medicine, you should read information on contraindications in the Package Leaflet of the medicine to be radiolabelled.

Warnings and precautions

For information concerning special warnings and special precautions for use of ^{68}Ga -labelled medicines please refer to the Package Leaflet of the medicine to be radiolabelled.

Children and adolescents

Please speak to your nuclear medicine doctor if you or your child are under 18 years old.

Other medicines and gallium (^{68}Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images by your doctor.

It is not known whether gallium (^{68}Ga) chloride solution may interact with other medicines as specified studies have not been carried out. You will not receive an injection of gallium (^{68}Ga) chloride, but a medicine radiolabelled with ^{68}Ga .

For information concerning other medicines in combination with the use of ^{68}Ga -labelled medicines, please read the Package Leaflet of the radiolabelled medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given ^{68}Ga -labelled medicines.

You must inform the nuclear medicine doctor before the administration of ^{68}Ga -labelled medicines if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.

When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

The nuclear medicine doctor will only administer a ^{68}Ga -labelled medicine during pregnancy if a benefit is expected which would outweigh the risks.

If you are breast-feeding

You will be asked to stop breast-feeding. Please ask your nuclear medicine doctor when you can resume breast-feeding.

Driving and using machines

There could be effects on your ability to drive and to use machines due to the use of ^{68}Ga -labelled medicines. Please read the Package Leaflets of these medicines carefully.

3. How gallium (^{68}Ga) chloride solution produced with GalliaPharm is used

There are strict laws on the use, handling, and disposal of radiopharmaceutical products. GalliaPharm will only be used in special controlled areas. The production of gallium (^{68}Ga) chloride solution, radiolabelling of a specific carrier medicine, as well as administration of ^{68}Ga -labelled medicine to you, will only be handled by people who are trained and qualified to use it safely. They will take special care for the safe use of this medicine and will keep you informed of their actions.

The nuclear medicine doctor supervising the procedure will decide on the amount of medicine radiolabelled with ^{68}Ga to be used in your case. It will be the smallest quantity necessary to achieve the appropriate outcome.

Administration of gallium (^{68}Ga) chloride solution and conduct of the procedure

You will not be given the gallium (^{68}Ga) chloride solution, but another medicine which has been combined (radiolabelled) with gallium (^{68}Ga) chloride solution.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure with a ^{68}Ga -labelled medicine. For more information, please read the Package Leaflet of the radiolabelled medicine.

After the medicine radiolabelled with gallium (^{68}Ga) chloride solution has been given

The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the ^{68}Ga -labelled medicine. Contact your nuclear medicine doctor if you have any questions.

If you have been given more medicine radiolabelled with gallium (^{68}Ga) chloride solution than you should, or have received direct injection of gallium (^{68}Ga) chloride solution inadvertently

An overdose, or inadvertent direct injection of gallium (^{68}Ga) chloride solution is unlikely, because you will only receive the ^{68}Ga -labelled medicine precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, or inadvertent direct injection you will receive the appropriate care.

Should you have any further questions on the use of this medicine, please ask the nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, the ^{68}Ga -labelled medicine can cause side effects, although not everybody gets them.

After the ^{68}Ga -labelled medicine is administered, it will deliver low amounts of ionising radiation with the least risk of cancer and hereditary abnormalities.

For more information about possible side effects, please read the Package Leaflet of the radiolabelled medicine.

Reporting of side effects

If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How GalliaPharm is stored

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only.

The radionuclide generator must not be used after the expiry date stated on the container after “EXP”.

Do not dismantle the case.

The gallium (^{68}Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Contents of the pack and other information

What GalliaPharm contains

- The active substance consists of germanium (^{68}Ge) chloride and gallium (^{68}Ga) chloride dissolved in sterile ultrapure 0.1 mol/l hydrochloric acid. Germanium (^{68}Ge) is irreversibly trapped inside the radionuclide generator decaying to its daughter nuclide (^{68}Ga), which is obtained from the generator as gallium (^{68}Ga) chloride.
- The other ingredients are: Titanium dioxide (matrix)
 Sterile ultrapure 0.1 mol/l hydrochloric acid (solution for elution)

One radionuclide generator is supplied with:

1. 1 x PP – container with the eluent, 250 ml sterile ultrapure 0.1 mol/l hydrochloric acid (including a separate hanger for PP-bottles; PP = Polypropylene)
2. 1 x Vented spike (ABS = Acrylonitrile Butadiene Styrene/PE = Polyethylene)
3. 2 x Adapter 1/16" to male LUER (PEEK)
4. 2 x Tubing 60 cm (PEEK)
5. 1 x Tubing 40 cm (PEEK)
6. 1 x Tubing 20 cm (PEEK)
7. 3 x Fingertight fitting 1/16" 10-32 (PEEK)
8. 1 x Fingertight fitting 1/16" M6 (PEEK)
9. 1 x Stopcock manifold (TPX = Polymethylpentene/HDPE = High Density Polyethylene)
10. 1 x Male LUER union (PP)

What GalliaPharm looks like and contents of the pack

You will not need to obtain or handle this medicine.

Marketing Authorisation Holder and Manufacturer

Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany

This leaflet was last revised in.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

<----->

The following information is intended for healthcare professionals only:

The complete SmPC of GalliaPharm is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.

Please refer to the SmPC.